4SC (VSC) Q1 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 earnings summary
6 Jun, 2025Executive summary
Focused on advancing resminostat (Kinselby) for advanced-stage CTCL, with EU approval as a key milestone.
MAA for resminostat filed with EMA; major objections received in March 2025, with further feedback pending.
No significant corporate events occurred in Q1 2025.
Cash position at €6.8 million as of 31 March 2025, sufficient for current projections into Q2 2026.
Licensing and partnering activities ongoing for non-core assets.
Financial highlights
Cash balance declined to €6.8 million from €8.3 million at year-end 2024.
Average monthly cash use from operations was €493 thousand in Q1 2025, down from €742 thousand in Q1 2024.
Cash usage within the forecasted range of €400–700 thousand per month.
Outlook and guidance
Awaiting further EMA feedback on resminostat MAA, expected in April 2025.
Filings in UK and Switzerland contingent on positive EMA opinion.
Sufficient cash runway projected into Q2 2026, subject to planning assumptions.
Latest events from 4SC
- Drug development halted, capital injection and delisting mark a critical transitional phase.VSC
Q3 2025 - Resminostat program ended; capital cut, delisting, and strategic review underway.VSC
Q2 2025 - Resminostat nears EU approval, with funding secured into 2026 and commercialization as key focus.VSC
Q3 2024 - Resminostat EMA review advances, EU focus, cost cuts, and new funding support operations.VSC
Q2 2024 - Kinselby nearly doubles progression-free survival in advanced CTCL, targeting EU approval.VSC
Corporate Presentation - EMA objections to resminostat approval put 4SC's future at significant risk.VSC
Q4 2024